<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757236</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO2011/LB/LIZ-BONE</org_study_id>
    <secondary_id>2012-000781-38</secondary_id>
    <nct_id>NCT01757236</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection</brief_title>
  <acronym>LIZ-BONE</acronym>
  <official_title>Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Clinical Trials Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of oral linezolid-rifampin combination
      therapy (over 4 or 6 weeks) versus the standard of care in the treatment of Gram-positive
      prosthetic hip joint infection with a one-stage surgical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>12 months after the end of treatment</time_frame>
    <description>Clinical cure rate in the modified intent-to-treat (mITT)population during the hospital visit. Patients will be declared cured if clinical signs of infection are normalized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate</measure>
    <time_frame>12 months after the end of treatment</time_frame>
    <description>Cure rate ine the modified intent-to-treat population during the hospital visit. Patients will be cdeclared cured if radiological and laboratory signs of infection are normalized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure rate</measure>
    <time_frame>6 and 24 months after the end of treatment for the modified intent-to-treat population and at 12 months for the per protocol population.</time_frame>
    <description>Patients will be declared cured if clinical, radiological, and laboratory signs of infection normalized.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hip Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).
Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).
Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).
The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VANCOMYCIN</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>VANCOCIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEFTRIAXONE</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>ROCEPHIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLINDAMYCIN</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>DALACIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>BACTRIM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLUOROQUINOLONE</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>OFLOCIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LINEZOLID</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>ZYVOXID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIFAMPIN</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>RIFADIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women ≥ 18 to ≤ 80 years of age, weight ≥ 40 kg, BMI &lt; 35, who have received a
             diagnosis of chronic PJI (lasting more than 4 weeks but less than 24 months) requiring
             a one-stage surgical procedure and presenting at least ONE of the following clinical
             signs and symptoms:

               1. Joint pain

               2. Effusion

               3. Erythema and sensation of heat at the implant site

               4. Limited range of motion in the affected joint

          2. Intraoperative microbiological specimens: during the surgical resection, 5 separate
             surgical specimens (at least 3) must be sent for culture and susceptibility testing.
             These specimens must be taken from different locations such as: Hip capsule, femoral
             membrane, acetabular membrane, synovium, and synovial fluid with separate instruments.
             A minimum of 2 surgical specimens must be positive. If a preoperative puncture
             revealed the presence of an acceptable (Gram+) pathogen, it is acceptable if only one
             pathogen similar to the previously revealed one is identified during the surgical
             procedure.

          3. Documented presence of Gram-positive bacteria as sole pathogen responsible for the
             infection.

             Note: This criterion must be verified after obtaining the results of the
             susceptibility test performed on the specimens taken during the surgical procedure.
             The verification will occur between Day 2 and Day 7 of the study.

          4. All patients must undergo 1-stage revision surgery.

          5. IRB or IEC approved informed consent form signed and dated. Informed consent will be
             obtained from each patient before participation in this research study. If any patient
             is unable to give consent, it may be obtained from the patient's next of kin or legal
             representative in accordance with current laws and regulations.

          6. Willing and able to comply with scheduled visits, up to 6 weeks of treatment with the
             study antibiotics, laboratory tests, and other study procedures.

          7. Patient entitled to Health System benefits or other such benefits

        Exclusion Criteria:

          1. Concerning women of childbearing age:

               1. intake of oral contraceptives (estroprogestins and progestins)

               2. unability to use adequate mechanical contraceptive precautions

               3. a positive pregnancy test result within 72 hours prior to randomization

               4. pregnant, or are currently breastfeeding and unwilling to discontinue
                  breastfeeding during therapy

          2. Patients with a prosthetic joint infection caused by: Gram-negative, mixed
             Gram-negative and Gram-positive, fungal, or mycobacterial microorganisms. If a
             previous radiologically guided puncture has revealed the presence of a Gram-negative
             microorganism, the patient must not be enrolled in this study.

          3. Platelet count less than 100 ×103/mm3 at the time of the examination performed during
             the screening period.

          4. Hemoglobin &lt; 9 g/dL at the time of the examination performed during the screening
             period.

          5. Infection affecting several joints.

          6. Rheumatological disease (e.g., rheumatoid arthritis, systemic lupus erythematosus,
             etc.)

          7. Previously diagnosed immune function disease(s) (e.g., AIDS), neutropenia (neutrophils
             &lt; 1000/mm3).

          8. Alcoholism or substance abuse sufficient, in the investigator's judgment, to prevent
             treatment adherence to the study drug and/or follow-up.

          9. Patients currently in peritoneal dialysis or receiving another treatment for renal
             failure (e.g., hemofiltration, CVVH).

         10. Liver failure with alanine aminotransferase (ALT) and/or aspartate aminotransferase
             (AST) and/or total bilirubin levels upper or egal to 5 times the upper limit of
             normal.

         11. Patients with other concurrent serious infections such as: endocarditis, meningitis,
             or central nervous system (CNS) infections, decubitus and ischemic ulcers with
             underlying osteomyelitis, necrotizing fasciitis, gas gangrene. If suspected, these
             diagnoses must be ruled out prior to enrollment in the study.

         12. Previous randomization in this protocol.

         13. Not expected or not likely to survive for the entire duration of the treatment period
             and TOC (12 months after the end of treatment).

         14. Hypersensitivity to the study drugs or their excipients.

         15. Identification of a pathogen resistant to the investigational drugs.

         16. Patients treated with a protease inhibitor(e.g. indinavir, ritonavir), or with
             delavirdine, or with nevirapine.

         17. Patients treated or having been treated within two weeks prior surgery with an MAOI (A
             or B), an antiserotonergic drug, a tricyclic antidepressant, an agonist of
             5HT1-receptor(triptan), a direct or indirect sympathomimetic drug (including
             adrenergic bronchodilator, pseudoephedrin, phenylpropanolamin), a vasopressor
             (adrenalin, noradrenalin), dopaminergic drug, pethidin or buspirone,

         18. Patients with a degenerative neurological disease (Parkinson's disease, multiple
             sclerosis, Alzheimer's disease, etc.).

         19. Patient presenting an uncontrolled hypertension, a pheochromocytoma, a carcinoid
             syndrome, a hyperthyroidism, a bipolar depression, a dysthymic schizophrenia, an acute
             confusional state, pophyria or a history of retrobulbar optic neuritis.

         20. Patient who is participating or has participated in a clinical trial in the month
             prior to the study screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis BERNARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Tours FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David BOUTOILLE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwenael LE MOAL</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Poitiers FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matteo BASSETTI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Opedaliera Universitaria San Maria della Misericordia ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvano ESPOSITO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facolta di Medicina e Chirugia ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeannot GAUDIAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Chirurgie Orthopédique et de la Main FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex SORIANO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona SPAIN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bartolome LLADO FERRER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llatzer Palma Balears SPAIN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mar SANCHEZ SOMOLINOS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HGU Gregorio Maranon Madrid SPAIN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric SENNEVILLE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Tourcoing FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louis BERNARD</last_name>
    <phone>+ 33 (0) 2 47 47 97 74</phone>
    <phone_ext>79774</phone_ext>
    <email>l.bernard@chu-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <state>Indre et Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis BERNARD</last_name>
      <phone>+33 (0) 2 47 47 97 74</phone>
      <email>l.bernard@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Louis BERNARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David BOUTOILLE</last_name>
    </contact>
    <investigator>
      <last_name>David BOUTOILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenaël LE MOAL</last_name>
    </contact>
    <investigator>
      <last_name>Gwenaël LE MOAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Chirurgie Orthopédique et de la Main</name>
      <address>
        <city>Strasbourg</city>
        <zip>67400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot GAUDIAS</last_name>
      <email>Jeannot.GAUDIAS@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jeannot GAUDIAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric SENNEVILLE</last_name>
      <email>esenneville@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Eric SENNEVILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Opedaliera Universitaria San Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo BASSETTI</last_name>
      <email>mattba@tin.it</email>
    </contact>
    <investigator>
      <last_name>Matteo BASSETTI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex SORIANO</last_name>
      <email>ASORIANO@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Alex SORIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mar SANCHEZ SOMOLINOS</last_name>
    </contact>
    <investigator>
      <last_name>Mar SANCHEZ SOMOLINOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bartolome LLADO FERRER</last_name>
    </contact>
    <investigator>
      <last_name>Bartolome LLADO FERRER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic</keyword>
  <keyword>linezolid</keyword>
  <keyword>linezolid/rifampin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

